Sources and further reading FDA evaluation of BPC-157-related bulk drug substances, 11 May 2026 FDA Pharmacy Compounding Advisory Committee briefing, July 2026 FDA: bulk drug substances that may present significant safety risks TGA and Australian Chief Medical Officer: unapproved peptide products, 19 June 2026 World Anti-Doping Agency: 2026 Prohibited List Early BPC research indexed by PubMed Review of BPC-157 and musculoskeletal soft-tissue healing Recent review calling for well-designed human trials Researcher, clinician or journalist
SARMs | Pros and Cons Scientists may wonder how peptides compare to SARMs in research settings when investigating muscle growth, weight loss, and recovery
Brain 128, 3541
As a clear indication, the Monastral Blue studies in ethanol damaged gastric rat mucosa are widely recognized due to the ability of Monastral Blue to bind to damaged endothelium
For the full BPC-157 dosing breakdown, see our BPC-157 dosage protocol guide: BPC-157: 200 to 500 mcg per day, subcutaneous injection near the injury site, 4 to 8 weeks TB-500 loading phase (Weeks 1-4): 2 to 5 mg twice per week TB-500 maintenance phase (Weeks 5-8): 2 mg once per week Route: Both peptides are administered via subcutaneous injection
